In a study from Herlev and Gentofe Hospital, scientists found COVID mRNA vaccines are linked to a decreased risk of death in patients with heart failure.
They also found that the vaccines were not linked to an increased risk of worsening heart failure, venous thromboembolism, or heart attack in heart failure patients.
Patients with heart failure are at increased risk of hospitalization, need for mechanical ventilation, and death due to COVID-19. Vaccination reduces the risk of serious illness from COVID-19.
In the study, the team examined 50,893 unvaccinated patients with heart failure and 50,893 patients with heart failure who were vaccinated with either of the two mRNA vaccines (BNT162B2 or mRNA-1273).
The age of participants was about 74 years and 35% were women. The duration of heart failure was about 4 years.
Participants were followed for 90 days for death, worsening heart failure, venous thromboembolism (blood clots in the veins), and heart attacks.
Among 101,786 heart failure patients, the researchers found that receiving an mRNA vaccine was not linked to an increased risk of worsening heart failure, blood clots, or heart failure but was linked to a decreased risk of death.
The standardized risk of all-cause mortality within 90 days was 2.2% in the 2021 cohort (vaccinated) and 2.6% in the 2019 cohort (not vaccinated).
The risk of worsening heart failure within 90 days was 1.1% in both groups. Similarly, no strong differences were found between groups for blood clots and heart attacks.
The team says the study suggests that there should be no concern about heart side effects from mRNA vaccines in heart failure patients. In addition, the results point to a beneficial effect of vaccination on mortality.
If you care about COVID, please read studies that aspirin, common anti-inflammatory drugs may prevent COVID-19 deaths, and aspirin could cut cancer death by 20%.
For more information about COVID, please see recent studies about common drug that may reduce your risk of COVID-19 infection, and results showing new antiviral drug 10 times more effective against COVID-19.
The study was conducted by Dr. Caroline Sindet-Pedersen et al and presented at ESC Congress 2022.
Copyright © 2022 Knowridge Science Report. All rights reserved.
